Corticosteroids in Kidney Transplant Recipients: Safety Issues and Timing of Discontinuation

Antonio Tarantino, Giuseppe Montagnino, Claudio Ponticelli

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Corticosteroids have played a key role in the immunosuppression of organ transplantation. Unfortunately, the extensive use of these agents has resulted in disabling and life-threatening adverse effects in many patients. The advent of concomitant corticosteroid/cyclosporin regimens has allowed a reduction in the dosages of steroids administered, yet steroid-induced morbidity is still a major problem in many cyclosporin-treated renal transplant patients. After favourable initial experiences with cyclosporin monotherapy, several attempts at steroid-free immunosuppression in renal transplant patients have been undertaken, either by not starting steroids after transplantation or by stopping steroids in patients with stable graft function. Most controlled and uncontrolled trials showed that with either strategy short term graft survival was similar with or without steroids, but acute rejection was more frequent in patients not taking steroids. The percentage of patients who could be maintained steroid-free ranged from 28 to 94%, and was higher in patients who stopped steroids later than in those never receiving them. Little information is available about long term follow-up of these patients. Some studies reported late attrition of renal function in patients not taking steroids, while others reported a favourable outcome even in the long term. Steroid-free immunosuppression is feasible in renal transplant patients, but it requires careful monitoring of renal function and cyclosporin dosage. This strategy is particularly indicated in patients at high risk of cardiovascular disease or steroid-related complications, and in children. Nevertheless, several issues need to be better elucidated by further studies, namely the long term outcome of steroid-free immunosuppression, the advantages and disadvantages of steroid avoidance versus steroid withdrawal, and the criteria for selecting patients.

Original languageEnglish
Pages (from-to)145-156
Number of pages12
JournalDrug Safety
Volume13
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Transplants
Adrenal Cortex Hormones
Steroids
Kidney
Safety
Immunosuppression
Cyclosporine
Transplant Recipients
Grafts
Transplantation (surgical)
Organ Transplantation
Graft Survival

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Public Health, Environmental and Occupational Health

Cite this

Corticosteroids in Kidney Transplant Recipients : Safety Issues and Timing of Discontinuation. / Tarantino, Antonio; Montagnino, Giuseppe; Ponticelli, Claudio.

In: Drug Safety, Vol. 13, No. 3, 1995, p. 145-156.

Research output: Contribution to journalArticle

Tarantino, Antonio ; Montagnino, Giuseppe ; Ponticelli, Claudio. / Corticosteroids in Kidney Transplant Recipients : Safety Issues and Timing of Discontinuation. In: Drug Safety. 1995 ; Vol. 13, No. 3. pp. 145-156.
@article{b123fa7e9d9d4307876a66c10eb4e485,
title = "Corticosteroids in Kidney Transplant Recipients: Safety Issues and Timing of Discontinuation",
abstract = "Corticosteroids have played a key role in the immunosuppression of organ transplantation. Unfortunately, the extensive use of these agents has resulted in disabling and life-threatening adverse effects in many patients. The advent of concomitant corticosteroid/cyclosporin regimens has allowed a reduction in the dosages of steroids administered, yet steroid-induced morbidity is still a major problem in many cyclosporin-treated renal transplant patients. After favourable initial experiences with cyclosporin monotherapy, several attempts at steroid-free immunosuppression in renal transplant patients have been undertaken, either by not starting steroids after transplantation or by stopping steroids in patients with stable graft function. Most controlled and uncontrolled trials showed that with either strategy short term graft survival was similar with or without steroids, but acute rejection was more frequent in patients not taking steroids. The percentage of patients who could be maintained steroid-free ranged from 28 to 94{\%}, and was higher in patients who stopped steroids later than in those never receiving them. Little information is available about long term follow-up of these patients. Some studies reported late attrition of renal function in patients not taking steroids, while others reported a favourable outcome even in the long term. Steroid-free immunosuppression is feasible in renal transplant patients, but it requires careful monitoring of renal function and cyclosporin dosage. This strategy is particularly indicated in patients at high risk of cardiovascular disease or steroid-related complications, and in children. Nevertheless, several issues need to be better elucidated by further studies, namely the long term outcome of steroid-free immunosuppression, the advantages and disadvantages of steroid avoidance versus steroid withdrawal, and the criteria for selecting patients.",
author = "Antonio Tarantino and Giuseppe Montagnino and Claudio Ponticelli",
year = "1995",
doi = "10.2165/00002018-199513030-00002",
language = "English",
volume = "13",
pages = "145--156",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Corticosteroids in Kidney Transplant Recipients

T2 - Safety Issues and Timing of Discontinuation

AU - Tarantino, Antonio

AU - Montagnino, Giuseppe

AU - Ponticelli, Claudio

PY - 1995

Y1 - 1995

N2 - Corticosteroids have played a key role in the immunosuppression of organ transplantation. Unfortunately, the extensive use of these agents has resulted in disabling and life-threatening adverse effects in many patients. The advent of concomitant corticosteroid/cyclosporin regimens has allowed a reduction in the dosages of steroids administered, yet steroid-induced morbidity is still a major problem in many cyclosporin-treated renal transplant patients. After favourable initial experiences with cyclosporin monotherapy, several attempts at steroid-free immunosuppression in renal transplant patients have been undertaken, either by not starting steroids after transplantation or by stopping steroids in patients with stable graft function. Most controlled and uncontrolled trials showed that with either strategy short term graft survival was similar with or without steroids, but acute rejection was more frequent in patients not taking steroids. The percentage of patients who could be maintained steroid-free ranged from 28 to 94%, and was higher in patients who stopped steroids later than in those never receiving them. Little information is available about long term follow-up of these patients. Some studies reported late attrition of renal function in patients not taking steroids, while others reported a favourable outcome even in the long term. Steroid-free immunosuppression is feasible in renal transplant patients, but it requires careful monitoring of renal function and cyclosporin dosage. This strategy is particularly indicated in patients at high risk of cardiovascular disease or steroid-related complications, and in children. Nevertheless, several issues need to be better elucidated by further studies, namely the long term outcome of steroid-free immunosuppression, the advantages and disadvantages of steroid avoidance versus steroid withdrawal, and the criteria for selecting patients.

AB - Corticosteroids have played a key role in the immunosuppression of organ transplantation. Unfortunately, the extensive use of these agents has resulted in disabling and life-threatening adverse effects in many patients. The advent of concomitant corticosteroid/cyclosporin regimens has allowed a reduction in the dosages of steroids administered, yet steroid-induced morbidity is still a major problem in many cyclosporin-treated renal transplant patients. After favourable initial experiences with cyclosporin monotherapy, several attempts at steroid-free immunosuppression in renal transplant patients have been undertaken, either by not starting steroids after transplantation or by stopping steroids in patients with stable graft function. Most controlled and uncontrolled trials showed that with either strategy short term graft survival was similar with or without steroids, but acute rejection was more frequent in patients not taking steroids. The percentage of patients who could be maintained steroid-free ranged from 28 to 94%, and was higher in patients who stopped steroids later than in those never receiving them. Little information is available about long term follow-up of these patients. Some studies reported late attrition of renal function in patients not taking steroids, while others reported a favourable outcome even in the long term. Steroid-free immunosuppression is feasible in renal transplant patients, but it requires careful monitoring of renal function and cyclosporin dosage. This strategy is particularly indicated in patients at high risk of cardiovascular disease or steroid-related complications, and in children. Nevertheless, several issues need to be better elucidated by further studies, namely the long term outcome of steroid-free immunosuppression, the advantages and disadvantages of steroid avoidance versus steroid withdrawal, and the criteria for selecting patients.

UR - http://www.scopus.com/inward/record.url?scp=0029083499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029083499&partnerID=8YFLogxK

U2 - 10.2165/00002018-199513030-00002

DO - 10.2165/00002018-199513030-00002

M3 - Article

C2 - 7495501

AN - SCOPUS:0029083499

VL - 13

SP - 145

EP - 156

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 3

ER -